In this edition:
Ribociclib + endocrine therapy in HR+/HER2- early breast cancer
Ovarian ablation or suppression and breast cancer recurrence
Evaluation of genetic subtypes in early-stage HR+ breast cancer
3-year invasive disease-free survival after chemotherapy de-escalation
CDK4/6 inhibitors for HR+, HER2- advanced breast cancer
Fixed vs standard dose capecitabine in metastatic breast cancer
Autonomous patient empowerment app and deterioration of QoL
Age-specific effect of trastuzumab deruxtecan for HER2+ metastatic breast cancer
A weight loss intervention in women with early breast cancer
Chemotherapy-induced peripheral neuropathy due to paclitaxel vs docetaxel
Please login below to download this issue (PDF)